Publications by authors named "Rainer Boxhammer"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

3,834

Total Likes

367

Extended Reach

3,457,519

Social Features

139
P
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
Raajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, Elisabetta Abruzzese, Prithviraj Bose, Rainer Boxhammer

Nat Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.
Brad H Rovin, Pierre M Ronco, Jack F M Wetzels, Sharon G Adler, Isabelle Ayoub, Rainer Boxhammer

Kidney Int Rep· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical study of CD19 detection methods post tafasitamab treatment.
Kristina Ilieva, Markus Eberl, Jan Jaehrling, Derek Blair, Maria Patra-Kneuer, Rainer Boxhammer

Front Immunol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.
Jung Hyun Her, Dominik Pretscher, Maria Patra-Kneuer, Juergen Schanzer, Sung Yoo Cho, Rainer Boxhammer

Cancer Immunol Immunother· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti-CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study.
Brad H Rovin, Rainer Boxhammer, Anjali Thakur, Pierre M Ronco

Kidney Int Rep· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
Katharina A Mayer, Klemens Budde, Philip F Halloran, Konstantin Doberer, Lionel Rostaing, Rainer Boxhammer

Trials· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway.
Leonhard Busch, Dimitrios Mougiakakos, Maike Büttner-Herold, Miriam J Müller, Dietrich A Volmer, Rainer Boxhammer

Leukemia· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.
Katharina Teiluf, Christof Seidl, Birgit Blechert, Florian C Gaertner, Klaus-Peter Gilbertz, Rainer Boxhammer

Oncotarget· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fully human antibodies against the Protease-Activated Receptor-2 (PAR-2) with anti-inflammatory activity.
Patricia Giblin, Rainer Boxhammer, Sudha Desai, Rachel Kroe-Barrett, Gale Hansen

Hum Antibodies· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis